The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the ... 7.6% of participants taking the placebo. “When Johnson & Johnson started researching Spravato ...
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback